Pharmaceuticals

Global Bevacizumab Biosimilars Industry Insights: Key Trends and Growth Estimates

February 12, 2026February 12, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the bevacizumab biosimilars market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Bevacizumab Biosimilars Market expected to reach by 2030?

The bevacizumab biosimilars market has demonstrated substantial growth in its size over recent years. It is projected to expand from $1.64 billion in 2025 to $1.77 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.5%. The expansion observed historically can be attributed to factors such as the patent expiry of reference bevacizumab, an increase in cancer prevalence, the demand for cost-effective biologics, government incentives for biosimilars, and advancements in recombinant DNA technology.

The market for bevacizumab biosimilars is projected to experience robust expansion over the coming years. Its valuation is anticipated to reach $2.42 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.2%. This anticipated growth during the forecast period is attributable to several factors, including a rise in biosimilar approvals, market expansion into developing regions, the incorporation of AI into drug development processes, a rising inclination towards outpatient oncology services, and strategic partnerships among pharmaceutical enterprises. Key trends expected during this period encompass a greater uptake of biosimilars within oncology, the availability of economical treatment options, an increase in regulatory approvals for biosimilars, the broadening of hospital and retail pharmacy infrastructures, and the proliferation of specialized cancer care facilities.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp

What Drivers Are Driving Adoption Within The Bevacizumab Biosimilars Market?

An increasing number of cancer cases is anticipated to boost the expansion of the bevacizumab biosimilar market in the future. Cancer incidence is defined as the count of newly identified cancer cases within a particular demographic over a certain timeframe. Bevacizumab, a biologic drug, works by inhibiting the formation of new blood vessels in tumors (angiogenesis), thereby contributing to tumor reduction and hindering its growth. Its effectiveness and safety for patients with advanced non-small cell lung cancer or metastatic colorectal cancer are on par with reference biologics. As an illustration, data from October 2025, provided by NHS England, a UK government body, indicated 354,820 new cancer diagnoses in England during 2023, representing an increase of 8,605 cases compared to 2022. Consequently, the growing incidence of cancer cases fuels the demand for the bevacizumab biosimilars market.

How Is The Bevacizumab Biosimilars Market Organized Into Various Segments?

The bevacizumab biosimilars market covered in this report is segmented –

1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer

Which Trends Are Influencing The Performance And Direction Of The Bevacizumab Biosimilars Market?

Major companies in the bevacizumab biosimilars market are concentrating on technological progress, such as advanced indication-expanded formulations, to satisfy the growing demand for more adaptable and affordable biologic therapies across oncology and non-oncology uses. These sophisticated formulations adapt the core bevacizumab antibody for new delivery methods or indications, allowing for non-oncologic application (like in ophthalmology) or more convenient patient dosing, while still utilizing the same VEGF-neutralizing mechanism found in traditional intravenous bevacizumab. For example, in March 2024, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, launched Versavo (bevacizumab) in the UK. This high-quality biosimilar of Avastin (bevacizumab) is intended for oncology applications, making treatments for metastatic colorectal cancer, lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer, and breast cancer more accessible and affordable for more patients. Versavo is supplied in 100 mg and 400 mg single-use vials, matching standard bevacizumab dosing while providing a biosimilar cost-benefit that aids in reducing the financial burden on healthcare systems and patients relying on anti-VEGF therapy.

Who Are The Major Companies Operating In The Bevacizumab Biosimilars Market?

Major companies operating in the bevacizumab biosimilars market are Cipla Limited, Reliance lifesciences Pvt. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., Apotex Inc., BioXpress Therapeutics SA, mAbxience SA

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Bevacizumab Biosimilars Market?

North America was the largest region in the bevacizumab biosimilars market in 2025. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Bevacizumab Biosimilars Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10848&type=smp

Browse Through More Reports Similar to the Global Bevacizumab Biosimilars Market 2026, By The Business Research Company

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Adalimumab Infliximab And Etanercept Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilars-market

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795